Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: AXIM

AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid Addiction Treatment

NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. The chewing gum may also be used for treatment of chronic pain.

“Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies. Opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the craving and reduces withdrawal symptoms, while maintaining the person’s mental state such that the person is still able to function …

Continue Reading

Posted in Client News| Tagged |

AXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency Study

NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company has secured $4 million of institutional funding to further advance its clinical trials for the treatment of Irritable Bowel Syndrome (IBS), pain and spasticity in Multiple Sclerosis (MS), and to continue a bio-equivalency study on creating an alternative to Marinol® using the company’s patented chewing-gum delivery system.

“This financing enables us to continue to build on the progress we have made with our cannabinoid clinical development program for indications where there are currently no effective treatments,” said George Anastassov, MD, DDS, MBA, and Chief Executive Officer of AXIM. “It is encouraging to see that investors recognize the potential of our robust clinical development pipeline. We are now better positioned to execute on cannabinoid research and commercialization.”

MedChew Rx™ is a THC/CBD controlled-release chewing …

Continue Reading

Posted in Client News| Tagged |

SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00

SAN DIEGO, May 17, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage initiation from SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies, with a price target of $17.00.

“We are thrilled to see a well respected Wall Street equities firm initiating coverage on AXIM Biotech,” said Dr. Stuart Titus, President and CEO of Medical Marijuana Inc. (OTC: MJNA).  “We have believed that AXIM would emerge as an up-and-coming biotech concern and quite excited about their cannabinoid research and pharmaceutical development activities.  It is thrilling to see the investment community taking notice of AXIM’s emerging story and perceiving future value for investors.”

The full research report is available here. Highlights from the report include:

Large market opportunity
The market …

Continue Reading

Posted in Client News| Tagged |
AXIM

Medical Cannabis-Based Gum Moves into Production for Clinical Trials

AXIM

As of May 2, 2017, one of the world leaders in cannabinoid research and development declared their product development partner, Quay Pharmaceuticals Ltd., also known as Quay Pharma, acquired a license from the British Home Office to continue research related to AXIM’s MedChew Rx® line of pharmaceutical chewing gum. This particular license allows the British-based pharmaceutical company to work with controlled drugs in order to continue with the development process of the product.

Currently, MedChew RX® is made with 5 mg of cannabidiol (CBD) as well as an equivalent dosage of tetrahydrocannabinol (THC). When the drug does hit the market, it’ll be used to treat pain and spasms in patients who have multiple sclerosis (MS). This particular condition is a degenerative disease that affects the central nervous system and disrupts how the brain and body communicate with one another. Current research published by the National Organization for the Reform …

Continue Reading

Posted in Articles| Tagged , , , |

Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum

SAN DIEGO, May 3, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc.’s (AXIM® Biotech) (OTC: AXIM) product development partner Quay Pharmaceuticals Ltd. (“Quay Pharma”) has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM MedChew Rx® pharmaceutical chewing gum products.

MedChew Rx® is being developed as a pharmaceutical drug to treat pain and spasticity associated with multiple sclerosis (MS). It is formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC).

The value of the MS treatment market is estimated to reach $20 billion by 2024, according to research firm GlobalData. This growth is primarily driven by the continued development of new products and an increase in diagnosis rates across …

Continue Reading

Posted in Client News| Tagged , , , |
AXIM Biotechnologies, Inc.

AXIM Biotechnologies, Inc. and API Develop Marinol Alternative

AXIM Biotechnologies, Inc.

Medical marijuana has presented life-changing treatment options for patients around the world, but with strict laws in many regions preventing the use of such pharmaceutical alternatives, progress has been gradual. There is still significant stigma surrounding the effects of medical marijuana and its use in a clinical treatment setting. Despite the many positive studies associated with these products, opposition persists in many sectors of the market. Companies such as AXIM Biotechnologies, Inc. (OTCQX: AXIM) have long been at the forefront of medical marijuana research and development, facing opposition from lobbyists and other detractors who seek to keep the status quo within the pharmaceutical industry. Until recently, Insys Therapeutics was one of those companies.

In the past, Insys Therapeutics has been active in the opposition of general marijuana legalization, donating $500,000 to a group called Arizonans for Responsible Drug Policy in the summer of 2016. The group launched a campaign …

Continue Reading

Posted in Articles| Tagged , , , |